NasdaqGM - Nasdaq Real Time Price USD

SCYNEXIS, Inc. (SCYX)

2.2200

-0.0700

(-3.06%)

At close: June 7 at 4:00 PM EDT

2.2100

-0.01

(-0.45%)

After hours: June 7 at 6:00 PM EDT

Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025

The ability to recognize possibilities while investing can frequently be the difference between stagnation and growth in an unstable and changing economic environment. Here are three exciting stocks in technology, insurance, and medicines. Leading the pack among these chances is the first, which has cleverly turned to utilize partnerships and licensing agreements to generate income. These tactical changes highlight a practical reaction to the difficulties and expenses of medicine marketing, even

InvestorPlace 8 days ago

IMMR

HRTG

SCYX
-3.06%
3 Stocks Under $10 With Mammoth Growth Prospects

Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential. These companies operate in a variety of industries, including technology and healthcare. They offer a unique opportunity to profit from rapid revenue growth, strong financial stability and well-thought-out development strategies. With a robust organic revenue increase in the first quarter and a solid focus on the hyaluronic acid

InvestorPlace 16 days ago

BVS

IMMR

SCYX
-3.06%
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would trigger a $10 million development milestone payment to SCYNEXISSCYNEXIS ended Q1 2024 with cash, cash equivalents and investments of $94.2 million and projects a cash runway of more than two years JERSEY CITY, N.J.,

GlobeNewswire last month

SCYX
-3.06%
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...

Simply Wall St. last month

SCYX
-3.06%
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentat

GlobeNewswire last month

SCYX
-3.06%
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024. SCY-247 is being developed to address sy

GlobeNewswire last month

SCYX
-3.06%
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analyses The clinical study reports for FURI, CARES and NATURE in refractory invasive fungal infections are on target for delivery to GSK in the first half of 2024 which would trigger a $10 million develo

GlobeNewswire 2 months ago

SCYX
-3.06%
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET. Guggenheim’s 6th Annual Biotechnology Conference Format: Fireside chat and one-on-one meetingsDate: Wed

GlobeNewswire 4 months ago

SCYX
-3.06%
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosisCombination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burden in lung and brain tissue compared to monotherapies JERSEY CITY, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and pr

GlobeNewswire 4 months ago

SCYX
-3.06%
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024. Poster Presentati

GlobeNewswire 5 months ago

SCYX
-3.06%
Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago

We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...

Simply Wall St. 6 months ago

SCYX
-3.06%
11 Cheapest Stocks With Biggest Upside

In this piece, we will take a look at the 11 cheapest stocks with the biggest upside. If you want to skip our introduction to stock valuation and recent market news, then take a look at 5 Cheapest Stocks With Biggest Upside. Identifying the right stocks to invest in is a science that involves evaluating […]

Insider Monkey 6 months ago

MEIP

NVDA

CTRM
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advanceRemediation strategies following the voluntary recall of BREXAFEMME® and the MARIO study clinical hold are being evaluatedWith cash, cash equivalents and investments of $105.2 million as of September 30, 2023, SCYNEXIS projects a cash runway of more than two years JERSEY CITY, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biote

GlobeNewswire 6 months ago

SCYX
-3.06%
SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens. The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve Universit

GlobeNewswire 7 months ago

SCYX
-3.06%
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece

JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM)

GlobeNewswire 7 months ago

SCYX
-3.06%
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance

BREXAFEMME Carton BREXAFEMME Blister Pack JERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the BREXAFEMME® tablets. During a review of manufacturing equipment and cleaning activities at a supplier, SCYNEXIS was ma

GlobeNewswire 8 months ago

SCYX
-3.06%
Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?

Verve Therapeutics (VERV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 8 months ago

VERV

SCYX
-3.06%
UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination risk

Scynexis said on Monday it would voluntarily recall its antifungal pill, which it has licensed to GSK, due to risk of cross-contamination with a potential allergy-inducing compound, sending the drugmaker's shares tumbling over 30%. The drugmaker said it became aware substances used to make drugs that contain beta-lactam are manufactured using equipment also used to make its treatment, called Brexafemme. The U.S. Food and Drug Administration's guidelines require companies to segregate the manufacturing of beta-lactam compounds from other drugs because they may trigger hypersensitivity or an allergic reaction in some people.

Reuters 8 months ago

SCYX
-3.06%
PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 8 months ago

PTCT

SCYX
-3.06%
SCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?

SCYNEXIS' (NASDAQ:SCYX) stock is up by a considerable 18% over the past three months. As most would know, fundamentals...

Simply Wall St. 8 months ago

SCYX
-3.06%

Performance Overview

Return	SCYX	S&P 500
YTD	-0.45%	+12.10%
1-Year	-8.64%	+24.82%
3-Year	-72.39%	+26.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SCYNEXIS, Inc. (SCYX)

Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025

3 Stocks Under $10 With Mammoth Growth Prospects

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago

11 Cheapest Stocks With Biggest Upside

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece

SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance

Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?

UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination risk

PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?

SCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?

Performance Overview